

Borislava Mihaylova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2850379/publications.pdf>

Version: 2024-02-01

77
papers

24,998
citations

201385

27
h-index

106150

65
g-index

77
all docs

77
docs citations

77
times ranked

21228
citing authors

#	ARTICLE	IF	CITATIONS
1	MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20â€™536 high-risk individuals: a randomised placebocontrolled trial. <i>Lancet, The</i> , 2002, 360, 7-22.	6.3	7,542
2	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	1.0	4,871
3	MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. <i>Lancet, The</i> , 2003, 361, 2005-2016.	6.3	2,587
4	The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. <i>Lancet, The</i> , 2012, 380, 581-590.	6.3	2,250
5	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019, 290, 140-205.	0.4	1,753
6	MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20â€™536 high-risk individuals: a randomised placebo-controlled trial. <i>Lancet, The</i> , 2002, 360, 23-33.	6.3	1,413
7	Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174â€™000 participants in 27 randomised trials. <i>Lancet, The</i> , 2015, 385, 1397-1405.	6.3	1,112
8	Review of statistical methods for analysing healthcare resources and costs. <i>Health Economics (United Kingdom)</i> , 2011, 20, 897-916.	0.8	574
9	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , 2019, 393, 407-415.	6.3	512
10	Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20â€™536 high-risk individuals: a randomised controlled trial. <i>Lancet, The</i> , 2011, 378, 2013-2020.	6.3	244
11	Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 829-839.	5.5	234
12	The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2021, 99, 34-47.	2.6	195
13	The impact of diabetesâ€™related complications on healthcare costs: new results from the UKPDS (UKPDS) Tj ETQq1 1 0.784314 rgBT 1.2 160	1.2	160
14	Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2015-2027.	3.0	140
15	Statins for people at low risk of cardiovascular disease â€™ Authors' reply. <i>Lancet, The</i> , 2012, 380, 1817-1818.	6.3	127
16	Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20â€™536 individuals. <i>Lancet, The</i> , 2005, 365, 1779-1785.	6.3	106
17	Body mass index and healthcare costs: a systematic literature review of individual participant data studies. <i>Obesity Reviews</i> , 2017, 18, 869-879.	3.1	91
18	THE EFFECT OF DIABETES COMPLICATIONS ON HEALTHâ€™RELATED QUALITY OF LIFE: THE IMPORTANCE OF LONGITUDINAL DATA TO ADDRESS PATIENT HETEROGENEITY. <i>Health Economics (United Kingdom)</i> , 2014, 23, 487-500.	0.8	84

#	ARTICLE	IF	CITATIONS
19	What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. BMC Nephrology, 2015, 16, 65.	0.8	82
20	Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20â€™536 people. BMJ: British Medical Journal, 2006, 333, 1145.	2.4	80
21	The impact of social disadvantage in moderate-to-severe chronic kidney disease: an equity-focused systematic review*. Nephrology Dialysis Transplantation, 2016, 31, 46-56.	0.4	76
22	Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)â€™A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. American Heart Journal, 2017, 187, 182-190.	1.2	66
23	Meta-analysis of the procedural risks of carotid endarterectomy and carotid artery stenting over time. British Journal of Surgery, 2017, 105, 26-36.	0.1	57
24	Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart, 2007, 93, 1081-1086.	1.2	53
25	Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. American Journal of Kidney Diseases, 2016, 67, 31-39.	2.1	42
26	Optimisation of Perioperative Cardiovascular Management to Improve Surgical Outcome II (OPTIMISE II) trial: study protocol for a multicentre international trial of cardiac output-guided fluid therapy with low-dose inotrope infusion compared with usual care in patients undergoing major elective gastrointestinal surgery. BMJ Open, 2019, 9, e023455.	0.8	35
27	Impact of <i>ADCY9</i> Genotype on Response to Anacetrapib. Circulation, 2019, 140, 891-898.	1.6	34
28	Hospital costs in relation to body-mass index in 1Âˆ1 million women in England: a prospective cohort study. Lancet Public Health, The, 2017, 2, e214-e222.	4.7	30
29	Content of Health Economics Analysis Plans (HEAPs) for Trial-Based Economic Evaluations: Expert Delphi Consensus Survey. Value in Health, 2021, 24, 539-547.	0.1	28
30	Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. European Heart Journal, 2022, 43, 1416-1424.	1.0	27
31	An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. Journal of Clinical Epidemiology, 2018, 99, 75-83.	2.4	25
32	Impact of CKD on Household Income. Kidney International Reports, 2018, 3, 610-618.	0.4	25
33	Health Economics Analysis Plans: Where Are We Now ?. Value in Health, 2016, 19, A397.	0.1	24
34	Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. American Heart Journal, 2016, 176, 63-69.	1.2	22
35	A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. Heart, 2017, 103, 1880-1890.	1.2	21
36	Impact of the 2003 to 2018 Population Salt Intake Reduction Program in England. Hypertension, 2021, 77, 1086-1094.	1.3	21

#	ARTICLE	IF	CITATIONS
37	Is Doctor Referral to a Low-Energy Total Diet Replacement Program Cost-Effective for the Routine Treatment of Obesity?. <i>Obesity</i> , 2019, 27, 391-398.	1.5	20
38	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016, 67, 576-584.	2.1	19
39	Socioeconomic differences in health-care use and outcomes for stroke and ischaemic heart disease in China during 2009-16: a prospective cohort study of 0.5 million adults. <i>The Lancet Global Health</i> , 2020, 8, e591-e602.	2.9	19
40	Cost-Effectiveness of Duloxetine: The Stress Urinary Incontinence Treatment (SUIT) Study. <i>Value in Health</i> , 2010, 13, 565-572.	0.1	14
41	The INVEST project: investigating the use of evidence synthesis in the design and analysis of clinical trials. <i>Trials</i> , 2017, 18, 219.	0.7	14
42	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. <i>Kidney International</i> , 2019, 96, 170-179.	2.6	13
43	Choices of Stent and Cerebral Protection in the Ongoing ACST-2 Trial: A Descriptive Study. <i>European Journal of Vascular and Endovascular Surgery</i> , 2017, 53, 617-625.	0.8	12
44	Body mass index and use and costs of primary care services among women aged 55-79 years in England: a cohort and linked data study. <i>International Journal of Obesity</i> , 2019, 43, 1839-1848.	1.6	11
45	Supported online self-management versus care as usual for symptoms of fatigue, pain and urgency/incontinence in adults with inflammatory bowel disease (IBD-BOOST): study protocol for a randomised controlled trial. <i>Trials</i> , 2021, 22, 516.	0.7	11
46	Cholesterol- and blood-pressure-lowering drug use for secondary cardiovascular prevention in 2004-2013 Europe. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 426-436.	0.8	10
47	Impact of achieving primary care targets in type 2 diabetes on health outcomes and healthcare costs. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2405-2412.	2.2	10
48	Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90). <i>Diabetic Medicine</i> , 2021, 38, e14656.	1.2	10
49	BMI and Cause-Specific Hospital Admissions and Costs: The UK Biobank Cohort Study. <i>Obesity</i> , 2020, 28, 1332-1341.	1.5	9
50	Decrements in health-related quality of life associated with adverse events in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 530-538.	2.2	9
51	Quantifying and Valuing Community Health Worker Time in Improving Access to Malaria Diagnosis and Treatment. <i>Clinical Infectious Diseases</i> , 2016, 63, S298-S305.	2.9	8
52	Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 348-354.	0.9	8
53	Out-of-Pocket Costs and Other Determinants of Access to Healthcare for Children with Febrile Illnesses: A Case-Control Study in Rural Tanzania. <i>PLoS ONE</i> , 2015, 10, e0122386.	1.1	8
54	Cost-Effectiveness of Pre-Referral Antimalarial, Antibacterial, and Combined Rectal Formulations for Severe Febrile Illness. <i>PLoS ONE</i> , 2010, 5, e14446.	1.1	7

#	ARTICLE	IF	CITATIONS
55	Are statins useful in patients with advanced chronic kidney disease? â€œ Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 971-972.	5.5	7
56	Long-term health outcomes of people with reduced kidney function in the UK: A modelling study using population health data. <i>PLoS Medicine</i> , 2020, 17, e1003478.	3.9	7
57	Impact of Improving Community-Based Access to Malaria Diagnosis and Treatment on Household Costs. <i>Clinical Infectious Diseases</i> , 2016, 63, S256-S263.	2.9	6
58	Hospital costs associated with adverse events in people with diabetes in the <sc>UK</sc>. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2108-2117.	2.2	5
59	Performance of the UK Prospective Diabetes Study Outcomes Model 2 in a Contemporary UK Type 2 Diabetes Trial Cohort. <i>Value in Health</i> , 2022, 25, 435-442.	0.1	4
60	Gender differences in use of invasive diagnostic and therapeutic procedures for acute ischaemic heart disease in Chinese adults. <i>Heart</i> , 2021, , heartjnl-2021-318988.	1.2	3
61	Daily Life and Challenges Faced By Households With Permanent Childhood Developmental Disability in Rural Tanzania â€œ A Qualitative Study. <i>Journal of Developmental and Physical Disabilities</i> , 2022, 34, 471-490.	1.0	3
62	Household costs and time to treatment for children with severe febrile illness in rural Burkina Faso: the role of rectal artesunate. <i>Malaria Journal</i> , 2018, 17, 380.	0.8	2
63	Gaps in antihypertensive and statin treatments and benefits of optimisation: a modelling study in a 1 million ethnically diverse urban population in UK. <i>BMJ Open</i> , 2021, 11, e052884.	0.8	2
64	FP329IMPACT OF EDUCATIONAL ATTAINMENT ON HEALTH OUTCOMES IN MODERATE-TO-SEVERE CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii178-iii178.	0.4	1
65	Long-term monitoring in primary care for chronic kidney disease and chronic heart failure: a multi-method research programme. <i>Programme Grants for Applied Research</i> , 2021, 9, 1-218.	0.4	1
66	Statistical models for the deterioration of kidney function in a primary care population: A retrospective database analysis. <i>F1000Research</i> , 0, 8, 1618.	0.8	1
67	Benefits from optimised antihypertensive and statin treatment in high risk people. <i>European Heart Journal</i> , 2021, 42, .	1.0	1
68	Authorsâ€™ Reply. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2602.2-2603.	3.0	0
69	Declining socioeconomic inequalities in hospital care use and case fatality rates for stroke and ischaemic heart disease in China during 2009â€“16: a prospective study of 0.5 million adults. <i>Lancet, The</i> , 2019, 394, S9.	6.3	0
70	A model of lifetime health outcomes in cardiovascular disease based on clinical trials and large cohorts. <i>European Heart Journal</i> , 2021, 42, .	1.0	0
71	P55 Excess Annual Hospital Costs Due to Cardiovascular Events in a Contemporary UK Population to Inform Health Technology Assessments. <i>Value in Health</i> , 2022, 25, S12.	0.1	0
72	P70 Calibrating Cardiovascular Disease Policy Model Using Large Cohort Data. <i>Value in Health</i> , 2022, 25, S16.	0.1	0

#	ARTICLE	IF	CITATIONS
73	Title is missing!. , 2020, 17, e1003478.		0
74	Title is missing!. , 2020, 17, e1003478.		0
75	Title is missing!. , 2020, 17, e1003478.		0
76	Title is missing!. , 2020, 17, e1003478.		0
77	Title is missing!. , 2020, 17, e1003478.		0